Kyle Crassini

Immunoglobulin G subclass deficiency and infection risk in 150 patients with chronic lymphocytic leukemia

Jane A. Freeman, Kyle Crassini, Giles Best et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2012 · 104 citations

Chronic Lymphocytic Leukemia, Immunodeficiencies, Immunology +17

Humoral immune failure defined by immunoglobulin class and immunoglobulin G subclass deficiency is associated with shorter treatment‐free and overall survival in Chronic Lymphocytic Leukaemia

Kyle Crassini, Eva Zhang, Shalini Balendran et al. · British Journal of Haematology · 2018 · 48 citations · Full text

Immunohematology, Immunodeficiencies, Immunology +22

<scp>MEK</scp>1/2 inhibition by binimetinib is effective as a single agent and potentiates the actions of Venetoclax and <scp>ABT</scp>‐737 under conditions that mimic the chronic lymphocytic leukaemia (<scp>CLL</scp>) tumour microenvironment

Kyle Crassini, Yandong Shen, William Stevenson et al. · British Journal of Haematology · 2018 · 24 citations · Full text

Inhibition of the Raf-1 kinase inhibitory protein (RKIP) by locostatin induces cell death and reduces the CXCR4-mediated migration of chronic lymphocytic leukemia cells

Kyle Crassini, Tahni Pyke, Yandong Shen et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2018 · 18 citations

Apoptosis, Immunology, Cell Death +21

The MEK1/2 inhibitor, MEKi-1, induces cell death in chronic lymphocytic leukemia cells under conditions that mimic the tumor microenvironment and is synergistic with fludarabine

Kyle Crassini, William Stevenson, Stephen P. Mulligan et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2015 · 16 citations

Mixed-phenotype Acute Leukemia, Immunology, Cell Death +16